
New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Since prediction market platforms such as Kalshi began offering trade markets on regulatory reviews and clinical trial outcomes earlier this year, the pharma sector must decide how to enforce policy and compliance among its employees.






